BeyondSpring Set to Present Key Findings at Major Global Events
BeyondSpring to Highlight Plinabulin at Global Conferences
BeyondSpring Inc. (NASDAQ: BYSI), a remarkable clinical-stage biopharmaceutical company, is excited to announce its upcoming oral and poster presentations at prestigious cancer conferences. One of the key highlights will be the efficacy data from the Dublin-3 Phase 3 study, which is set to take place during the 2024 World Conference on Lung Cancer. This presentation will focus on the effectiveness of Plinabulin in combination with docetaxel as a treatment for non-small cell lung cancer (NSCLC).
Key Presentation Details at the 2024 World Conference on Lung Cancer
Scheduled for September 9, 2024, in San Diego, California, the oral presentation titled "Plinabulin/Docetaxel vs. Docetaxel in 2L/3L NSCLC after Platinum Regimens (DUBLIN-3): A Phase 3 Randomized Controlled Trial" will delve into the innovative treatments being explored in the fight against cancer. Dr. Trevor M. Feinstein, the principal investigator for the Dublin-3 study, will lead the presentation.
- Presenter: Dr. Trevor M. Feinstein
- Time: September 9, 2024, from 10:57 AM to 11:07 AM PDT
- Session: OA08. The New Generation of Cytotoxics
Posters to Showcase Additional Research at ESMO Congress 2024
In addition to the oral presentation, BeyondSpring will also host two poster presentations during the European Society for Medical Oncology (ESMO) Congress 2024 on September 14, 2024, in Barcelona, Spain.
Notable Poster Presentations
- Poster (1358P): This study will discuss the survival benefits of Plinabulin/Docetaxel versus traditional docetaxel treatment in EGFR wild-type NSCLC patients. Presentation will take place from 9 AM to 6:30 PM CEST.
- Poster (1330P): This will cover a Phase 2 study evaluating Plinabulin in combination with pembrolizumab and docetaxel for metastatic NSCLC patients who are progressing after first-line therapies. Similar to the other session, this poster will also run from 9 AM to 6:30 PM CEST.
About Plinabulin and Its Development
Plinabulin is a first-in-class asset developed by BeyondSpring, playing a crucial role in inducing dendritic cell maturation, which is vital for effective cancer treatment. Primarily targeted for use in NSCLC, this promising therapy is undergoing extensive clinical trials to ascertain its potential in improving patient outcomes.
BeyondSpring's clinical pipeline also includes several preclinical immuno-oncology assets, reinforcing its commitment to addressing significant medical challenges with innovative therapies.
About Dublin-3 Study
The Dublin-3 NSCLC study is a pivotal Phase 3 trial that compared the efficacy of Plinabulin combined with docetaxel against docetaxel alone in patients who did not respond to platinum doublet therapies. Evaluating survival rates and progression-free survival, this study aims to support more effective treatment protocols for NSCLC.
About Study 303
Concurrently, Study 303 is focusing on the efficacy of Plinabulin in conjunction with pembrolizumab and docetaxel for patients experiencing progression after previous treatments. Conducted at the Peking Union Medical College Hospital, this research seeks to establish a robust safety profile and positive efficacy results for metastatic NSCLC.
Frequently Asked Questions
What is BeyondSpring Inc.?
BeyondSpring Inc. is a clinical-stage biopharmaceutical company focusing on innovative cancer therapies aimed at enhancing clinical outcomes for patients.
What is Plinabulin?
Plinabulin is an anti-cancer agent developed by BeyondSpring that induces dendritic cell maturation, playing a significant role in cancer treatment methodologies.
When will the presentations take place?
The oral presentation is scheduled for September 9, 2024, at the World Conference on Lung Cancer, with poster presentations on September 14, 2024, at the ESMO Congress.
Who are the presenters for these studies?
Dr. Trevor M. Feinstein will present at the World Conference, while Dr. Yan Xu will present during the ESMO Congress.
How does the Dublin-3 study impact cancer treatment?
The Dublin-3 study aims to evaluate the efficacy of combining Plinabulin with existing treatments, potentially leading to improved outcomes for NSCLC patients.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Related Articles
- Plastic Caps and Closures Market Set to Reach USD 96.28 Billion
- Global PET-CT Scanner Market Set for $4.9 Billion Growth
- SS Innovations' First Mantra Surgical System Sale in Latin America
- Constellation Brands Revises Fiscal 2025 Financial Outlook
- RecycLiCo Battery Materials Appoints Dr. Maryam Rasouli as Principal Engineer
- Procaps Group Outlines Strategic Vision for Future Success
- GLOBO Language Solutions Explores AI in Medical Interpretation
- DemandScience Achieves a Historic 11th Inc. 5000 Honor
- Object Management Group Launches New Journal of Innovation
- Altamira Therapeutics Attends H.C. Wainwright Conference 2024
- Healthcare Mobility Solutions Market Foresees Major Growth
- Sustainable Apparel Market Projected to Hit USD 24.53 Billion
- Bio-Based Coatings Market Growth Driven by Eco-Friendly Demand
- Fleet Management Software Market Growth to USD 93.17 Billion
- Optical Modulators Market Growth Metrics and Key Drivers
- The Surging Mixed Reality Market: Predicted to Hit USD 76.91 Billion
- ChartPath and WoundZoom Partner to Revolutionize Wound Care
- Global Cash Handling Device Market Growth Insights
- Nutricosmetics Market Expected to Exceed $16.93 Billion Growth
- Affiliated Network Providers and Aurora Health Join Forces
- Ignitis Group Greenlights 174 MW Solar Project in Latvia
- Johnny Clark Welcomes EFFO: The Ultimate Frying Oil Solution
- Ignitis Group Commits to 174 MW Tume Solar Project
- Caristo Diagnostics Recognized as a Quarterfinalist for Digital Health Award
- INmune Bio Inc. Joins Baird 2024 Global Healthcare Conference
Recent Articles
- Plastic Caps and Closures Market Set to Reach USD 96.28 Billion
- IR Spectroscopy Market Growth Predictions Highlighted by R&D
- John Ballantyne Joins Glucotrack Board to Advance Innovation
- Avenue Therapeutics Announces Participation in Investor Conferences
- VCI Global Secures $18 Million Contract for IPO Listings
- Trust Stamp's Direct Offering Brings $2 Million for Growth
- PTC Welcomes Rob Bernshteyn to the Board of Directors
- PhaseV to Showcase Innovative Clinical Trial Solutions
- DiaCarta Advances MPOX Testing with FDA-EUA-Approved Kits
- Schwab Insights: Boost Your Retirement Savings Effectively
- Nvidia's Stellar Growth: Should You Buy Shares Now?
- Worksport's Dealer Initiative Drives Strong Sales Growth
- Navigating Risks for Bullish Investors this September
- Power Over Ethernet Lighting Market Expected to Surpass $1.3 Bn
- Troilus Gold Reports Encouraging Drill Results from West Rim Zone
- Blackwell 3D Advances Corporate Growth and Asian Expansion Plans
- REMSleep Secures Patent Approval for Nasal Ventilation System
- Clearlake Capital Expands Global Private Credit with MV Credit Acquisition
- Clearlake Capital Strengthens Leadership with Key Senior Appointments
- System Integration Market Set for 13.5% Growth by 2033
- Esports World Cup Foundation Partners with Media Groups
- Nokia Partners with AT&T for Fiber Broadband Growth Initiative
- Introducing the MEGAMINI G1: A Water-Cooled Gaming Revolution
- Scania Unveils Next-Gen 13-Litre Marine Engine for Sustainability
- AMSilk Joins the World Economic Forum's Global Innovators Community